SureTrader SureTrader
Home > Boards > US OTC > Medical - Healthcare >

Guided Therapeutics, Inc. (GTHP)

Add GTHP Price Alert      Hide Sticky   Hide Intro
Search This Board:
Last Post: 10/25/2016 10:36:17 AM - Followers: 100 - Board type: Free - Posts Today: 3

 Guided Therapeutics, Inc.

About Us

Early Detection, Better Outcomes

Guided Therapeutics, Inc. has developed a platform technology for the early detection of disease that leads to cancer. Based on our patented biophotonic technology, the products use light to detect disease at the cellular level and provide painless and immediate results at the time of the examination.

Testing for cancer today usually involves a taking a tissue sample, like a biopsy, and sending it out to a specialist at a laboratory for results. Patients worry while waiting on test results and in many instances are given the wrong diagnosis – in most cases a false-positive result. A false positive diagnosis means the patient will undergo more testing only to discover later that they are healthy.

Our technology non-invasively scans the suspicious tissue with cool white light providing results, that studies have shown, can detect pre-cancer up to two years earlier than the tissue-sample method and with fewer false-positive results. This means less pain, no time waiting for results and fewer unnecessary treatments.

LuViva® Advanced Cervical Scan

Distributor Map

LuViva has distribution in 47 countries, with U.S. FDA review underway.

Our first non-invasive cancer detection product is the LuViva® Advanced Cervical Scan. LuViva is in use in Canada, Latin America, Europe, Asia and Africa and is under premarket application (PMA) review by the U.S. Food and Drug Administration.

LuViva is designed to determine the true likelihood of treatable cervical disease that may lead to cancer in women aged 16 years and over who have been screened for cervical cancer and have an abnormal result. About 80% or more women with an abnormal result at this point in the testing process will eventually be diagnosed as having a false positive result – but after having an unnecessary colposcopy and biopsy. A one-minute scan with LuViva can rule out about 40% of the false-positive cases immediately without the need for colposcopy and biopsy. LuViva has also been shown in clinical trials to identify disease up to two years earlier than colposcopy and biopsy.

LuViva has also shown promise as a potential screening tool in the developing world to be used where the Pap test or HPV test are not widely available.  A clinical trial is underway to expand LuViva’s capabilities as a non-invasive cervical cancer screening product.

Cervical Cancer is a Big, Global Problem

After breast cancer, cervical cancer is the second most common cancer affecting women’s health. It is a leading cause of cancer deaths in the developing world for women of childbearing age.

Incidence of Cervical Cancer Worldwide:

  • 528,000 cases of invasive cancer (2012)
    266,000 deaths (2012)

In the U.S.:

  • 500,000 cases of precancer
    12,360 cases of cancer annually (2014)
    4,020 women will die from cervical cancer (2014)
    55-60 million Pap tests annually
    5.5-6 million follow-up referrals

Screening and diagnosis are effective but costly in developed regions of the world.  Common screening methods that lead to additional testing are positive for human papillomavirus (HPV) or an abnormal Pap test (cytology).

In developing regions, where screening methods are less commonly available, there is a different story.

“In sub-Saharan Africa, 34.8 new cases of cervical cancer are diagnosed per 100 000 women annually, and 22.5 per 100 000 women die from the disease. These figures compare with 6.6 and 2.5 per 100 000 women, respectively, in North America. The drastic differences can be explained by lack of access to effective screening and to services that facilitate early detection and treatment,” World Health Organization report.

Improving Cervical Cancer Detection with LuViva

Testing for cervical cancer today in the developed world involves taking a tissue sample – like a Pap test (cytology) for screening or a biopsy for diagnosis and sending the samples to a laboratory where they are read by a medical specialist. Results can take several days or weeks, delaying treatment and creating a time of uncertainty for the patient and her family.

In the developing world it’s a different story. Screening programs may be limited to a portion of the population in the larger cities with almost no screening is the rural areas.

LuViva can improve care in both situations.

In the Developed World:

Up to 80% or more of colposcopies and biopsies for for women who have abnormal Pap tests are found later to be normal or not necessary.  If HPV is used for screening those rates could go up.

Unmet Clinical Need for LuViva:  A non-invasive “triage” product to determine which patients that screen positive with Pap/HPV need a biopsy (true positives) and which don’t (normal or false positive).

In the Developing World:

Cervical cancer remains a leading cause of cancer death for women of childbearing age due to the lack of laboratory infrastructure.

Unmet Clinical Need for LuViva:  A non-invasive “screening” product that provides an immediate result in countries with little Pap/HPV screening.

Other Cancers

The platform technology that is LuViva can be applied to other forms or carcinoma. We’ve conducted human testing with the technology on patients at risk for esophageal cancer with promising results.  While a great deal more testing and development work needs to be done on that product, we believe that there is a need for our technology in the esophageal market.

Other cancers, in addition to cervical and esophageal, where the technology can be applied:

  • Head and Neck Cancer
    Anal Cancer
    Colorectal Cancer
    Skin Cancer

Our Business Model

Our business model is based on sales of a device, in this case the LuViva® Advanced Cervical Scan and a single-use, disposable patient interface called the Cervical Guide.  The continuing revenue from the Cervical Guides provides value for our shareholders. The Cervical Guide provides calibration of the LuViva before each test and assures the patient of a cross-contamination free examination.

Read more about our value propositions.

The Guided Therapeutics LuViva® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use.



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
GTHP News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 09/23/2016 02:54:06 PM
GTHP News: Current Report Filing (8-k) 09/23/2016 02:49:28 PM
GTHP News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 09/09/2016 10:13:01 AM
GTHP News: Amended Current Report Filing (8-k/a) 09/09/2016 10:04:59 AM
GTHP News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 09/08/2016 04:27:39 PM
#3988   Wow this board died quick yesterdaysnews74 10/25/16 10:36:17 AM
#3987   Wow this board died quick yesterdaysnews74 10/25/16 10:36:15 AM
#3986   How and why is this still above 5s yesterdaysnews74 10/25/16 09:49:55 AM
#3985   Will be in the 4s next week, should yesterdaysnews74 10/21/16 04:03:51 PM
#3984   Made my bet before first RS, lost.... I'll doncamel 10/20/16 10:32:14 PM
#3983   I don't think any work has been done Zeppo 10/20/16 12:47:36 PM
#3982   Seems to me it is best to wait duderaja 10/20/16 12:01:33 PM
#3981   I was here for first reverse split and doncamel 10/17/16 08:36:00 AM
#3980   Chinese FDA approval is any time now and Moe money 02 10/16/16 06:27:32 PM
#3979   FDA approval is NOT going to happen anytime yesterdaysnews74 10/16/16 12:08:37 PM
#3978   FDA approval will take this to $1.00 RS Moe money 02 10/14/16 02:23:48 PM
#3977   Are you on meds, do the math, the yesterdaysnews74 10/14/16 01:11:50 PM
#3976   I will stick to my $5.00 thank you. Moe money 02 10/14/16 01:03:43 PM
#3975   LOL! Try $.56 if pps stays at $.0007, yesterdaysnews74 10/14/16 12:11:17 PM
#3974   At $5.00 that sounds good to me. Moe money 02 10/14/16 11:41:23 AM
#3973   You mean 6250 after reverse! yesterdaysnews74 10/14/16 09:57:55 AM
#3972   I'm holding my 5M all the way no Moe money 02 10/13/16 02:15:41 PM
#3971   I think I'm just going to hold what Dgoff 10/13/16 11:54:29 AM
#3970   If the $.0006 wall falls, cant see post yesterdaysnews74 10/12/16 10:56:53 AM
#3969   $.0007s, getting closer to avg. The movement up shows yesterdaysnews74 10/11/16 01:32:01 PM
#3968   Reverse must be right around the corner with yesterdaysnews74 10/11/16 11:38:18 AM
#3967   May see $.0005s today! yesterdaysnews74 10/11/16 10:36:08 AM
#3966   Company able to keep this up today due yesterdaysnews74 10/10/16 12:40:14 PM
#3965   I have seen no corporate reference to a Zeppo 10/06/16 10:17:44 AM
#3964   Don't think you have seen the bottom yet, yesterdaysnews74 10/05/16 07:37:26 PM
#3963   Agree. No secondment, then no need to reverse Rkmatters 10/05/16 01:04:52 PM
#3962   They will only do the R/S if they Lwe6638 10/05/16 12:35:18 PM
#3961   I replied to your post yesterday. I think Rkmatters 10/04/16 02:49:41 PM
#3960   Be sure reverse is coming and probably without yesterdaysnews74 10/04/16 02:46:40 PM
#3959   L2s are so thin on the ask, could yesterdaysnews74 10/03/16 02:07:34 PM
#3958   Hi Lwe, Do we know the R/S date yet? Rkmatters 10/03/16 07:48:13 AM
#3957   Little dilution and likely trip zeros yesterdaysnews74 09/30/16 01:35:48 PM
#3956   Just need it to break the 1 million yesterdaysnews74 09/28/16 12:12:17 PM
#3955   Triple zeros coming this week yesterdaysnews74 09/28/16 11:49:32 AM
#3954   Watch the price go back down right back josemaria 09/27/16 07:45:07 AM
#3953   My needs share price as high as Lwe6638 09/26/16 11:20:20 PM
#3952   How is this still getting buying action, it's yesterdaysnews74 09/26/16 05:09:18 PM
#3951   8k Lwe6638 09/25/16 06:20:52 PM
#3950   That blows , 1/800 , you load and josemaria 09/25/16 06:00:51 PM
#3949   Reverse coming and 192 million outstanding shares, get yesterdaysnews74 09/25/16 05:31:10 PM
#3948   Where did you get this information from ? josemaria 09/25/16 11:02:17 AM
#3947   Why are people painting this green when it yesterdaysnews74 09/23/16 03:35:58 PM
#3946   Per company, shareholder meeting held today and RS passed. Lwe6638 09/23/16 02:16:20 PM
#3945   Trip zeros are almost reached. Expect $.0004s prior reverse yesterdaysnews74 09/23/16 11:58:22 AM
#3944   Rkmatters.... You have been very quiet....what are your thoughts Lwe6638 09/22/16 11:31:57 AM
#3943   Gut check time.... Lwe6638 09/21/16 12:20:28 PM
#3942   Might as well put this company in the yesterdaysnews74 09/19/16 10:00:05 PM
#3941   I hear your spin all the time, but duderaja 09/15/16 07:53:00 PM
#3940   Reverse coming and a guaranteed 5 million dilution yesterdaysnews74 09/15/16 11:58:21 AM
#3939   Is it correct that there are 153 million OS? duderaja 09/15/16 09:01:45 AM